We report here an IgG/λ-type plasma cell leukemia patient showing bialleic 14q32 translocations. All immunoglobulins were suppressed in this patient, but a small amount of monoclonal IgG was detected by immunoelectrophoresis. Two cells of six peripheral blood mononuclear cells showed 46,XY,t(2;14)(q11;q32), i(8)(q10), t(11;14)(q13;q32), del(12)(q13.1) by karyotypic analysis. We confirmed the juxtaposition of IgH and PRAD1/Cyclin D1 genes by fluorescent in situ hybridization and overexpression of the PRAD1/Cyclin D1 gene, but Southern analysis showed no bcl-1 rearrangement. We analyzed the t(2;14)(q11;q32) using DNA fragments derived from childhood B-chronic lymphocytic leukemia cases bearing t(2;14)(p13;q32). Southern and Northern analyses demonstrated no alteration of these genes, indicating that this t(2;14) was different from that of childhood B-chronic lymphocytic leukemia. At the IgH loci, Southern analysis showed two rearranged bands and one germ-line band of JH. Cμ was deleted on one rearranged allele but remained on the other, suggesting that the chromosome translocation occurred after productive class switch recombination on the Cμ deleted allele.

Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL, Kuehl WM: Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci USA 1996;93:13931–13936.
Nishida K, Tamura A, Nakazawa N, Ueda Y, Abe T, Matsuda F, Kashima K, Taniwaki M: The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood 1997;90:526–534.
Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM, Bergsagel PL: Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma: Association with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997;16:260–264.
Richelda R, Ronchetti D, Baldini L, Cro L, Viggiano L, Marzella R, Rocchi M, Otsuki T, Lombardi L, Maiolo AT, Neri A: A novel chromosomal translocation t(4;14)(p16.3;q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood 1997;90:4062–4070.
Iida S, Rao PH, Butler M, Corradini P, Boccadoro M, Klein B, Chaganti RSK, Dalla-Favera R: Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet 1997;17:226.
Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994;84:1361–1392.
Sawyer JR, Waldron JA, Jagannath S, Barlogie B: Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995;82:41–49.
Lai JL, Zandecki M, Mary JY, Bernardi F, Izydorczyk V, Flactif M, Morel P, Jouet JP, Bauters F, Facon T: Improved cytogenetics in multiple myeloma: A study of 151 patients including 117 patients at diagnosis. Blood 1995;85:2490–2497.
Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH, Naucke S, Sawyer JR: Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995;86:4250–4256.
Weh HJ, Bartl R, Seeger D, Selbach J, Kuse R, Hossfeld DK: Correlations between karyotype and cytologic findings in multiple myeloma. Leukemia 1995;9:2119–2122.
Kobayashi H, Saito H, Kitano K, Kiyosawa K, Gaun S, Aoki K, Narita A, Watanabe M, Uchimaru K, Motokura T: Overexpression of the PRAD1 oncogene in a patient with multiple myeloma and t(11;14)(q13;q32). Acta Haematol 1995;94:199–203.
Meeus P, Stul MS, Mecucci C, Cassiman JJ, Van den Berghe H: Molecular breakpoints of t(11;14)(q13;q32) in multiple myeloma. Cancer Genet Cytogenet 1995;83:25–27.
Shimazaki C, Goto H, Araki S, Tatsumi T, Takahashi R, Hirai H, Kikuta T, Yamagata N, Ashihara E, Inaba T, Fujita N, Suzuki R, Nakagawa M: Overexpression of PRAD1/cyclin D1 in plasma cell leukemia with t(11;14)(q13;q32). Int J Hematol 1997;66:111–115.
Chesi M, Bergsagel PL, Brents LA, Smith CA, Gerhard DS, Kuehl WM: Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 1996;88:674–681.
Heim S, Miteleman F: Multiple myeloma and plasma cell leukemia in chronic lymphoproliferative disorders; in Heim S, Miteleman F (eds): Cancer Cytogenetics, ed 2. New York, Wiley-Liss, 1995, pp 237–265.
Vaandrager JW, Kluin P, Schuuring E: The (t(11;14)(q13;q32) in multiple myeloma cell line KMS12 has its 11q13 breakpoint 330 kb centrometric from the cyclin D1 gene. Blood 1997;89:349–350.
Yoffe G, Howard-Peebles PN, Smith RG, Tucker PW, Buchanan GR: Childhood chronic lymphocytic leukemia with (2;14) translocation. J Pediatr 1990;116:114–117.
Sonnier JA, Buchanan GR, Howard-Peebles PN, Rutledge J, Smith RG: Chromosomal translocation involving the immunoglobulin kappa-chain and heavy-chain loci in a child with chronic lymphocytic leukemia. N Engl J Med 1983;309:590–594.
Richardson AL, Humphries CG, Tucker PW: Molecular cloning and characterization of the t(2;14) translocation associated with childhood chronic lymphocytic leukemia. Oncogene 1992;7:961–970.
Nishida K, Taniwaki M, Misawa S, Abe T: Nonrandom rearrangement of chromosome 14 at band q32.33 in human lymphoid malignancies with mature B-cell phenotype. Cancer Res 1989;49:1275–1281.
Lautner-Rieske A, Hameister H, Barbi G, Zachau HG: Mapping immunoglobulin gene-related DNA probes to the central region of normal and pericentrically inverted human chromosome 2. Genomics 1993;16:497–502.
An International System for Human Cytogenetic Nomenclature (ISCN 1995): Report of the standing committee on human cytogenetic nomenclature. Cytogenet Cell Genet 1995;31:1.
Takashima T, Itoh M, Ueda Y, Nishida K, Tamaki T, Misawa S, Abe T, Seto M, Machii T, Taniwaki M: Detection of 14q32.33 translocation and t(11;14) in interphase nuclei of chronic B-cell leukemia/lymphomas by in situ hybridization. Int J Cancer 1997;72:31–38.
Tsujimoto Y, Yunis J, Onorato-Showe L, Erikson J, Novell PC, Croce CM: Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. Science 1984;224:1403–1406.
Sonoki T, Hata H, Kuribayashi N, Yoshida M, Harada N, Nagasaki A, Kimura T, Matsuno F, Mitsuya H, Matsuzaki H: Expression of PRAD1/Cyclin D1 in plasma cell malignancy: Incidence and prognostic aspects. Br J Haematol 1999;104:614–617.
Ohtsuki T, Yawata Y, Wada H, Sugihara T, Mori M, Namba M: Two human myeloma cell lines, amylase-producing KMS-12PE and amylase-non-producing KMS-12BM, were established from a patient, having the same chromosome marker, t(11;14)(q13;q32). Br J Haematol 1989;73:199–204.
Matsuzaki H, Hata H, Asou N, Suzushima H, Akahoshi Y, Yoshida M, Nagakura S, Ishii T, Sanada I, Takatsuki K: Establishment and characterization of acute B-cell lymphocytic leukemia cell line showing (8;14) and (14;18) chromosome translocation. Acta Haematol 1990;84:156–161.
Hallek M, Bergsagel PL, Anderson KC: Multiple myeloma: Increasing evidence for a multistep transformation process. Blood 1998;91:3–21.
Kawano MM, Mahmoud MS, Ishikawa H: Cyclin D1 and p16INK4A are preferentially expressed in immature and mature myeloma cells, respectively. Br J Haematol 1997;99:131–138.
Zhang J, Alt FW, Honjo T: Regulation of class switch recombination of the immunoglobulin heavy chain genes; in Honjo T, Alt FW (eds): Immunoglobulin genes, ed 2. London, Academic Press, 1995, pp 235–265.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.